Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bristol Myers Squibb : Swings to 4Q Loss, Beats Sales Expectations

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2020 | 07:40am EDT

By Dave Sebastian

Bristol-Myers Squibb Co. (BMY) swung to a fourth-quarter loss as its expenses increased, though it beat adjusted-earnings and sales expectations.

The pharmaceutical company on Thursday posted a net loss of $1.06 billion, or 55 cents a share, compared with net income of $1.16 billion, or 71 cents a share, in the same quarter last year. Adjusted earnings were $1.22 a share.

Analysts polled by FactSet were expecting earnings of 85 cents a share, or 88 cents a share on an adjusted basis.

Revenue for the quarter was $7.95 billion, compared with $5.97 billion in the prior year, driven by the acquisition of Celgene Corp. that closed on Nov. 20. Analysts were looking for $7.12 billion.

Expenses rose to $8.07 billion from $4.47 billion in the comparable period last year.

Bristol last Friday said it withdrew its application in the European Union for the combination of Opdivo and Yervoy for the treatment of advanced non-small cell lung cancer. EU regulators turned Bristol's application away due to protocol changes in its CheckMate-227 study, the company said.

Write to Dave Sebastian at dave.sebastian@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 4.21% 57.87 Delayed Quote.-9.85%
CELGENE 0.10% 108.24 Delayed Quote.68.89%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BRISTOL-MYERS SQUIBB COMPA
10:32aACCELERON PHARMA : Bristol-Myers Shares Up After New FDA Nod for Reblozyl
DJ
05:25aBRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Reblozyl, the ..
AQ
04/03BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration (FDA) Approves Reblozyl..
BU
04/02BRISTOL-MYERS SQUIBB COMPANY : Ex-dividend day for
FA
04/01BRISTOL MYERS SQUIBB : and bluebird bio Announce Submission of Biologics License..
AQ
03/31BRISTOL MYERS SQUIBB : Bluebird Submit Biologics License Application for Idecabt..
DJ
03/31BRISTOL MYERS SQUIBB : and bluebird bio Announce Submission of Biologics License..
BU
03/31CYTOMX THERAPEUTICS : Announces Milestone Achievement in AbbVie CD71 Partnership..
AQ
03/30BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Approval of Z..
AQ
03/27BRISTOL MYERS SQUIBB : Myers Gets Positive CHMP Opinion for Zeposia
DJ
More news
Financials (USD)
Sales 2019 26 418 M
EBIT 2019 8 540 M
Net income 2019 -
Debt 2019 40 977 M
Yield 2019 3,00%
P/E ratio 2019 -
P/E ratio 2020 60,0x
EV / Sales2019 6,28x
EV / Sales2020 3,56x
Capitalization 125 B
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 69,36  $
Last Close Price 55,21  $
Spread / Highest target 43,1%
Spread / Average Target 25,6%
Spread / Lowest Target -9,44%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Michael Grobstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-9.85%126 110
JOHNSON & JOHNSON-8.02%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-16.16%195 141
NOVARTIS-11.15%187 703
PFIZER, INC.-14.14%181 075